The efficacy of pharmacological treatment in pediatric nonalcoholic Fatty liver disease. - Wikidata - awgldk - TriplyDB

The efficacy of pharmacological treatment in pediatric nonalcoholic Fatty liver disease.

The efficacy of pharmacological treatment in pediatric nonalcoholic Fatty liver disease.

http://www.wikidata.org/entity/Q37101542

about

Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease.Clinical significance of serum alanine aminotransferase and lifestyle intervention in children with nonalcoholic fatty liver disease.Fatty liver in childhood.

P2860

Q35124962-2D99E5EF-7AE2-4D64-9C60-47767F7E245E Q37313872-F2A4DADE-BF5C-4BDC-B101-7B753137CF1D Q37636566-69CFEB64-A70A-430B-82B7-FD9501228A87

P2860

The efficacy of pharmacological treatment in pediatric nonalcoholic Fatty liver disease.

http://www.wikidata.org/entity/Q37101542

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 31 December 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

The efficacy of pharmacological treatment in pediatric nonalcoholic Fatty liver disease.

@en

The efficacy of pharmacological treatment in pediatric nonalcoholic Fatty liver disease.

@nl

type

label

The efficacy of pharmacological treatment in pediatric nonalcoholic Fatty liver disease.

@en

The efficacy of pharmacological treatment in pediatric nonalcoholic Fatty liver disease.

@nl

prefLabel

The efficacy of pharmacological treatment in pediatric nonalcoholic Fatty liver disease.

@en

The efficacy of pharmacological treatment in pediatric nonalcoholic Fatty liver disease.

@nl

P1433

Q37101542-7A3CF7AE-0916-447B-902D-57E135C108A7

P1476

Q37101542-38D30B72-B215-4B8B-ADC4-FA7FD8BF7C6A

P2093

Q37101542-0B49CFB4-F26B-44C6-81D9-CDAA4DFA881A

Q37101542-36E3BA8D-4464-446C-8503-D316E0FF4F14

Q37101542-7291483B-3167-4A76-98C2-003B16BC1D40

P2860

Q37101542-139D4B75-CF04-490E-9CAF-75FEC27D5598

Q37101542-162BCAB3-49AF-4F45-AB27-28F1D6B4ECFC

Q37101542-19BB0A03-EA28-42F5-A785-53AE58195910

Q37101542-26E3F9B2-198B-449F-8500-2FD99B929BC2

Q37101542-2B1ED625-F4FB-4CB4-8B5C-9A567F8F8FB0

Q37101542-3A421DC8-8A8E-49C4-9A8A-D42D71D56442

Q37101542-3F280EA5-6DDD-40D6-82D5-B368A413A14C

Q37101542-4274B7AA-9C66-4DC1-AFAE-EC05D2039FEF

Q37101542-5CD9476A-5996-496A-98B2-B3C54F39F77B

Q37101542-602CE5B9-9985-4452-8975-042C9E795E2D

P304

Q37101542-AF9BD98E-A4FD-4A2A-AA72-C8481D73AD88

P31

Q37101542-B751E8D0-29FB-43F4-B0C1-CC644763212E

P356

Q37101542-BC121150-E50F-4840-AA68-8EEA399DB6EB

P433

Q37101542-3201B74F-7043-4688-9019-6518B137982A

P478

Q37101542-8A79B129-12B9-45BF-971C-199E1C494E38

P577

Q37101542-B86470AF-06F0-439D-9E8E-2D7786FAE149

P5875

Q37101542-E7F79084-9512-4D8F-B26B-E557B3157DBD

P698

Q37101542-ACF00089-8938-40A6-A8E5-A51222FC26ED

P921

Q37101542-F2DC0A18-57F1-44EB-BFB3-3EA5D53193CD

P932

Q37101542-C3DF9C32-A6F9-4215-AF51-F4C0984C330D

P356

PGHN.2012.15.4.256

P1433

Pediatric gastroenterology, hepatology & nutrition

P1476

The efficacy of pharmacological treatment in pediatric nonalcoholic Fatty liver disease.

@en

P2093

Seung Sam Paik

http://www.w3.org/2001/XMLSchema#string

Taeshik Cho

http://www.w3.org/2001/XMLSchema#string

Yong Joo Kim

http://www.w3.org/2001/XMLSchema#string

P2860

NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

Effect of the volume and intensity of exercise training on insulin sensitivity.

Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.

Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease.

Advances in pediatric nonalcoholic fatty liver disease.

Nonalcoholic fatty liver disease: a challenge for pediatricians.

High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial.

P304

256-265

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5223/PGHN.2012.15.4.256

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256447089

http://www.w3.org/2001/XMLSchema#string

P698

24010096

http://www.w3.org/2001/XMLSchema#string

P921

P932

3746059

http://www.w3.org/2001/XMLSchema#string